GERN — Geron Corporation

Geron Corporation Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Net Revenue: $51.8 million for Q1 2026, up 31% year-over-year and 8% quarter-over-quarter.
• Gross to Net Reductions: Increased to 21% from 13% year-over-year due to wider 340B utilization and expanded GPO contracting.
• Operating Expenses: Total operating expenses were $50.4 million, down 9% year-over-year, reflecting financial discipline.
• Cash Position: Approximately $341 million in cash, down from $401 million at the end of 2025, primarily due to annual bonuses and severance payments.
• 2026 Financial Guidance: Reiterated net revenue guidance of $220 million to $240 million and total operating expenses of $230 million to $240 million.

2. Strategic Updates and Business Highlights

• RYTELO Growth: Focused on increasing awareness and education among healthcare professionals in the U.S. and exploring European market opportunities.
• Leadership Changes: Strengthened management team with new Chief Legal Officer and two new Board members.
• Commercial Strategy: Emphasized targeted engagement with high-volume accounts and investment in digital marketing to enhance RYTELO's market presence.
• Clinical Engagement: Continued collaboration with the hematology community to support research and real-world evidence studies, including upcoming presentations at major medical meetings.

3. Forward Guidance and Outlook

• Growth Expectations: Anticipate continued demand growth for RYTELO, particularly in the second half of 2026 as marketing initiatives take effect.
• European Market Strategy: Exploring various options for RYTELO's commercialization in Europe, with plans to update the market by year-end.
• IMpactMF Trial: Fully enrolled, with an interim analysis expected in the second half of 2026, which could positively influence RYTELO's perception in the MDS market.

4. Bad News, Challenges, or Points of Concern

• Cash Decrease: The decline in cash reserves due to severance payments and CMC investments raises concerns about financial flexibility.
• Gross to Net Pressure: Increasing gross to net reductions may impact future profitability as the business matures.
• Market Competition: The need to establish a strong presence in Europe amidst a competitive landscape and pricing challenges remains a significant hurdle.

5. Notable Q&A Insights

• MF Interim Analysis: Management is cautious about revealing specific data from the IMpactMF trial until the analysis is complete, but they believe positive outcomes could enhance RYTELO's market position.
• Adoption Strategies: Efforts to increase RYTELO's adoption in earlier treatment lines are ongoing, with a focus on educational initiatives to drive prescribing patterns.
• Business Development: While open to opportunities, the primary focus remains on RYTELO's growth, with no immediate plans for acquisitions or partnerships unless they align with strategic goals.

This summary encapsulates Geron Corporation's financial performance, strategic initiatives, and outlook while addressing potential challenges and insights from the Q&A session.